Picture of Celltrion Healthcare Co logo

091990 — Celltrion Healthcare Co News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge Cap

Cigna to add three Humira biosimilars to drug reimbursement list (updated)

(Adds background on drugs, PBM, in paragraphs 3-5)
       July 10 (Reuters) - Cigna Group's  CI.N  Express Scripts
will add three biosimilars of AbbVie's  ABBV.N  blockbuster
arthritis treatment Humira to its list of preferred drugs, the
company said on Monday.
    The biosimilars include Hyrimoz and an unbranded version of
Humira from Swiss company Novartis'  NOVN.S  generics division
Sandoz, as well as German drugmaker Boehringer's Cyltezo. 
    Express Scripts, the pharmacy benefits management (PBM)
business of Cigna's Evernorth unit, said the biosimilars would
be included as preferred brands on the PBM's formulary or its
drug reimbursement list. 
    The drugs, launched in July, added to competition for Humira
in the U.S. that started in January with the launch of Amgen's
 AMGN.O  Amjevita, which is already on Express Scripts'
reimbursement list. 
    Organon  OGN.N , Coherus BioSciences  CHRS.O  and South
Korea's Celltrion  091990.KQ  have also launched their Humira
biosimilars.   
    PBMs act as middlemen and negotiate rebates and fees with
drug manufacturers, create lists of medications that are covered
by insurance, and reimburse pharmacies for patients'
prescriptions.



 (Reporting by Raghav Mahobe in Bengaluru; Editing by Shinjini
Ganguli and Sriraj)
 ((Raghav.Mahobe@thomsonreuters.com;))

Recent news on Celltrion Healthcare Co

See all news